SUMMARY : Effects of mixing living BCG with living tumor cells on the growth of the tumor cells in the intradermally inoculated mice and induction of the tumor immunity were investigated with various syngeneic and allogeneic mouse tumor systems. Tumor immunity was assessed from transplant resistance against challenge tumor grafts, macrophage migration inhibition and peritoneal macrophage disappearance.
INTRODUCTION
Zbar et al. (1970 a, 1971 b) reported that the intradermal growth of syngeneic hepatocarcinoma (line-10) in guinea pigs (strain 2) was suppressed when inoculated with living BCG. The BCG-tumor cell mixture also induced the tumor-specific immunity, characterized by delayed cutaneous hypersensitivity and rejection of challenged tumor cells of the same line. Tanaka and Tokunaga (1971) stated in a preliminary note that these might generally be true in syngeneic murine tumors. Bartlett , Zbar and Rapp (1972 a) , however, showed markedly contrasted effects of a BCG-tumor cell mixture on the murine and the guinea pig systems : namely injection with a mixture of BCG and murine tumor cells (line-1038) did not induce any higher tumor immunity than with the tumor cells alone.
In this investigation, various syngeneic and allogeneic murine tumors have been 
RESULTS

Suppression of Growth of Various Tumors at Sites of Intradermal Inoculation with Living BCG-Tumor Cell Mixtures and Rejection o f Challenge Tumor Grafts
Studies were made with the various murine tumors to find whether BCG-tumor cell mixture could prevent growth of the tumors and whether the animals suppressing tumor growth at the primary injection sites would subsequently reject challenge grafts of the tumors. The routine procedures were as follows : mice sensitized or unsensitized to BCG were given intradermal injections with either a mixture of approximately 106 viable tumor cells and 107 colony-forming units of BCG or 106 tumor cells alone. Each of the animals, bearing no visible tumor at the injection sites, was challenged, usually in 4 weeks by intradermal injection with 106 viable tumor cells at the sites contralateral to the primary injection.
The results with 5180 tumor system are illustrated in Fig mice were divided into four groups; two were sensitized to BCG and other two nonsensitized. One of the sensitized and of the nonsensitized groups were gi ven with the BCG-S180 mixture and the remainders with S180 alone . In the group inoculated with S180 alone, the tumor grew progressively in both sensitized and nonsensitized mice, killing them ultimately. However , the growth rate of the tumor was significantly lower in the sensitized group than in the nonsensitized one . Intradermal injections with the BCG-S180 mixture into both groups produced nodules at the i njection sites but those regressed within 20 days after the inoculation . These animals, h aving shown the regression of the tumor , were challenged intradermally each with 106 viable S180 cells at the contralateral site 60 days after the primary gr afting. All the animals suppressed the growth of the challenge grafts , while the tumors grew progressively in the control mice.
Such rejections of both primary and secondary tumor -grafts as observed with 5180 were not always the cases in other tumor systems as seen in Table II . Among syngeneic tumors, MCA-2 , K1 and K3 showed results similar to those with S180; most mice having received BCG-tumor cell mixtures rejected the tumor cell s and resisted the challenge tumor grafts . On the other hand , MCA-1, K5, M3 and With the former three tumors , most mice showed regression of the primary tumor growth when BCG was mixed before the injections, but few of them developed resistance against the secondary tumor grafts.
In the case of 4NQO-1, only few mice rejected the primary tumor graft ; even those having been sensitized to BCG and grafted with cells mixed with BCG before injections did not reject it. Of allogeneic tumors, Ehrlich gave results similar to those with S180 and L1210 behaved like 4NQO-1.
Factors Influencing the Effects of BCG-Tumor Cell Mixtures
In addition to the different effects of BCG-tumor cell mixtures seen among different tumor systems, some other factors also influenced the effects : a) Prior sensitization to BCG. Prior sensitization to BCG did not significantly impair the growth of syngeneic tumors. However, as seen in Table II , this factor was important for suppression of tumor growth at the injection sites of BCG-tumor cell mixtures, particularly in the cases of MCA-1, K2. K5 and M3. In 4NQO-1 , the effect of prior sensitization was not remarkable when BCG was injected together with 106 tumor cells (Table II) .
When a BCG-tumor cell mixture containing 105 tumor cells was employed, the effect of prior sensitization was remarkable; three of five sensitized mice rejected the primary grafts, while no unsensitized mice did so (Table III) .
Intradermal injection with L1210 cells mixed with BCG killed all the animals , even when such a small number as 104 of the tumor cells were injected into BCGsensitized mice. Survival time of those mice was prolonged significantly comparing to that of BCG-sensitized and nonsensitized mice injected with L1210 cells alone (Table IV) .
There seemed to be no difference in the potency of inducing tumor-specific immunity exhibited by resistance to secondary tumor grafts between BCG-sensitized and nonsensitized animals (Table II) .
b) The number of tumor cells contained in the BCG-tumor cell mixtur. The number of tumor cells contained in BCG-tumor cell mixtures was also an important factor affecting suppression of tumor growth at the sites of injection. Table III  shows (Table II) . c) Routes of injection with BCG-tumor cell mixture and direct contact of BCG and tumor cells. Route of injection with the BCG-tumor cell mixture was also important for rejection of the primary tumor grafts.
Incidences of tumor death in the mice injected by various routes with a mixture of BCG and Ehrlich ascites cells are shown in Table V . Tumor incidence was about 22 % when a mixture was given intradermally, 40 % when given subcutaneously, and 100 % when given intraperitoneally. To know whether contact between BCG and tumor cells is necessary for suppression of tumor growth at the primary injection sites, mice were given intradermal injections with BCG and tumor cells at the same site or at separate contralateral sites. The results with K3 tumor are shown in Table V . Only the mice injected simultaneously with BCG at the same site suppressed the tumor growth. Similar results were obtained with MCA-1, indicating that contact between BCG and tumor cells is required for suppression of primary tumor grafts.
Specificity of Tumor Immunity Induced with BCG-Tumor Cell Mixtures as Measured by Suppression of Challenge Tumor Grafts
To know whether or not tumor immunity induced by intradermal injection with BCG-tumor cell mixture is tumor-specific or not, SWM/Ms mice immunized with a mixture of K3 or K5 with BCG were challenged by intradermal injections with K3 and K5 tumor cells separately at contralateral sites. The results obtained are shown in Fig. 2 and Table VI. The challenged K3 tumor cells grew progressively in the K5-immunized and the untreated control mice at almost the equal growth rates, but they were rejected in most of the K3-immunized mice. On the other hand, K5 tumor cells challenged into the K3-or K5-immunized mice grew progressively but at a lower Tests for peritoneal macrophage disappearance were performed in mice immunized with BCG alone, BCG plus K3 or BCG plus K5 tumor cells. These animals were injected with PPD or a suspension of K3 or K5 antigen. Percentage of macrophages to the total cell population was calculated in each mouse and plotted in Fig. 3 . An injection with K3 or K5 antigen caused some fall in the macrophage content of the exudate of normal mice. The macrophage contents of the mice immunized with BCG plus K3 or K5 were lower than those of the control mice when the corresponding antigenic suspension was injected, also suggesting the presence of cell-mediated tumor immunity.
DISCUSSION
Active immunotherapy of malignant tumors with living BCG has extensively been investigated.
From the mode of administration with BCG, immunotherapy can be divided into the following three categories : (1) Dermal scarification or intradermal injection with BCG into the normal skin of tumor-bearing patients or animals; (2) Injection with BCG directly into established, solid tumors; (3) Intradermal injection with a mixture of BCG and tumor cells. Remarkable effects of the first technique on acute lymphoblastic leukaemia was first described by Mathe et al. (1969) and subsequently many investigators used this method and reported their clinical experiences (Mathe, 1971 (Mathe, , 1972 ; Leukaemic Committee and Working Party on Leukaemia in Childhood, 1971) . Marked effects of the second method, intralesional injections with living BCG, was described by Mortorn et al. (1970) in human melanoma ; the technique has been used by many clinicians (Morton et al. , 1971; Bluming et al. , 1972 ; Pinsky et al., 1972; Sulit et al., 1972) . In experimental tumors, this method was first employed by Zbar and Tanaka (1971 a) for a syngeneic guinea pig tumor, and then by Bartlett et al. (1972 a) for a syngeneic mouse tumor.
The present authors attempted at treating autochthonous mouse tumors by this method ; more than 100 SMW/Ms mice bearing tumors induced by MCA were injected intralesionally once with living BCG (Tokunaga, Yamamoto, Kataoka and Nakamura, unpublished data). In approximately 20 % of the mice injcted with BCG, regression of the established autochthonous tumors was observed; most of them, however, relapsed at the same or different sites within several weeks after disappearance. The last method, intradermal injection with a BCG-tumor cell mixture, was employed by Zbar et al. (1970 a) for the syngeneic guinea pig tumor system and has extensively been investigated (Zbar et al. , 1971 b ; Bartlett et al., 1972 b ; Simmons es al., 1971; Schwarz et al., 1971) . Living BCG mixed with tumor cells (line-10 of strain 2 guinea pigs) in the inoculum suppressed the growth of the tumor cells and injection of the mixture induced tumorspecific immunity manifested by delayed cutaneous hypersensitivity and rejection of inoculated tumor cells (Zbar et al., 1971 b) . A tumor-specific vaccine (Bartlett et al., 1972 b) was studied for the safety and therapeutic potency. Tanaka and Tokunaga (1971) reported preliminarily that these were also true in the syngeneic mouse systems. Some clinical trials were also performed by this technique (Morton et al., 1971; Sokal et al., 1972) . This method, if effective generally in inducing tumor-specific immunity, can be used clinically to prevent metastasis and relapse. Bartlett et al. (1972) , however, raised a question about the general efficacy of this method. They observed that a mixture of tumor cells (line 1038) and BCG did not effectively induce tumor specific immunity in syngeneic mice, although they gave no answer to the question whether this was a common feature of the mouse tumor system or it simply reflected a peculiar behavior of this tumor line.
In the present study, various syngeneic and allogeneic mouse tumors were examined to see if the effect of BCG-tumor cell mixtures on the growth of primary and secondary tumor grafts could be generalized.
The results demonstrated clearly that the effects of BCG-tumor cell mixture depend upon the tumor lines and also 19?3  TUMOR  IMMUNITY  WITH  BCG AND  TUMOR  CELLS  IN MICE upon the experimental conditions employed. The tumors employed seemed to fall into the following three types from the modes of effects of BCG-tumor cell mixtures as shown in Table II: (1) Such tumor cells that were rejected at the site of injection with a BCG-tumor cell mixture and developed subsequent transplant resistance to a challenged tumor graft in the animal, similar to the one reported in the guinea pig system (Zbar et al., 1971 b) ; (2) Such tumor cells whose intradermal growth was rejected at the injection site of a BCGtumor cell mixture, but induced no subsequent tumor immunity, resembling the line 1038 mouse tumor (Bartlett et al., 1972 a) ; (3) Such tumor cells that were not rejected nor induced detectable tumor immunity.
Syngeneic tumors of Ki, K2, K3 and MCA-2 and allogeneic tumors of 5180 and Ehrlich seemed to belong to the first type ; syngeneic tumors of K5, MCA-1 and M3 seemed to belong to the second type ; and both syngeneic 4NQO-1 and allogeneic L1210 belonged to the third type.
Difference among these types, however, is not essential, because the effects of BCG-tumor cell mixtures were influenced by other factors; for instance, tumor 4NQO-1 could have been included into the second type if a mixture containing 104 tumor cells, instead of 106 cells, had been given.
When a large number of cells of K3, K5 or 4NQO-1 were irradiated with 15,000 rad from Cobalt-60 and injected into mice without BCG, the animals developed various levels of resistance against challenged tumor grafts ; irradiated K3 cells induced a relatively strong resistance against transplant with K3, irradiated K5 cells evoked a significant but weak resistance against challenged K5 cells, but irradiated 4NQO-1 cells induced no detectable immunity (Nakamura, Kataoka, Yamamoto and Tokunaka, unpublished data). These results may suggest that among the three tumors, the antigenicity of K3 cells is the highest, that of K5 intermediate and that of 4NQO-1 the lowest. It was also noticed that the growth rates of these tumors are different; K5 cells grow much faster than K3 cells and 4NQO-1 cells grow still faster than K5 cells. These data suggest that the antigenicities and growth rates of the tumors seem to play important roles in exhibiting the effects of the BCG-tumor cell mixtures.
The role of BCG contained in the BCG-tumor cell mixtures may consist of two different mechanisms. First, BCG triggers off provoking BCG-specific, cellular reactions at the injection sites.
The resulting inflammatory reactions may destroy the tumor cells at the reaction sites nonspecifically.
In the animals sensitized to BCG, the reactions arise much more rapidly and vigorously than in nonsensitized animals. Zbar and his co-workers presented enough evidences to propose this two-step mechanism, nonspecific destruction of tumor cells with BCG-specific reactions (Zbar et al., 1970 (Zbar et al., b, c, 1971 Hanna, Zbar and Rapp, 1972 a, b ; Bartlett et al., 1972 a, b) . The notion of nonspecific inhibition is supported by the facts that prior sensitization to BCG is required to ensure the suppression of tumor growth at the primary injection sites and that mice can reject tumor cells but develop no tumor immunity with K5 , MCA-1 and M3. Histopathological findings in the time-course experiments with the BCG-K3 tumor system also supported the notion of nonspecific destruction of the tumor cells (Takahashi, Kataoka, Yamamoto, Nakamura and Tokunaga , unpublised data).
Secondly, BCG generally acts as an adjuvant enhancing both cellular and humoral immunity.
In addition, it is known that a delayed-type inflammatory reaction itself could exhibit adjuvant activity inducing delayed hyperse nsitivity under certain condi-tions; for instance, an intradermal injection with a mixture of PPD and BSA into a BCG-sensitized guinea pig induced delayed cutaneous hypersensitivity to BSA after four weeks (Bloom, 1969; Kataoka, Tokunaga and Yamamoto, unpublished data) . In the BCG-tumor cell systems, the tumor-specific antigen at the reaction sites evoked by BCG could be recognized effectively by the host.
Consequently, cell-mediated tumor immunity is induced and manifested by the rejection of challenged tumor grafts and by the in vitro tests.
If the antigenicity of the tumor is too weak to be recognized, if the tumor antigen is destroyed too early, or if antigenic competition occurs between tumor cells and BCG, the tumor specific immunity would not be induced.
Although more prompt and vigorous reaction is seen in BCG-sensitized animals at the site of injection with a BCG-tumor cell mixture than in nonsensitized ones and the reaction suppresses the tumor growth effectively, it has not been clarified whether this reaction effectively induces the tumor-specific immunity.
Further studies on the development of tumorspecific, cellular and humoral immunity in the host animals injected with BCG-tumor cell mixtures are in progress.
